Published on 6 May 2024 on Simply Wall St. via Yahoo Finance

Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at Travere Therapeutics, Inc.'s (NASDAQ:TVTX) future prospects. Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. With the latest financial year loss of US$376m and a trailing-twelve-month loss of US$416m, the US$514m market-cap company amplified its loss by moving further away from its breakeven target. As path to profitability is the topic on Travere Therapeutics' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for Travere Therapeutics